• Xianfeng Chen, Juntao Hu, Yiping Pan, and Zhanhong Tang.
• Department of Intensive Care Unit, The First Affiliated Hospital of Guangxi Medical University, Nanning, PR China.
• Expert Rev Respir Med. 2020 Mar 1; 14 (3): 299-306.

AbstractIntroduction: Acute respiratory distress syndrome (ARDS) is a very common condition associated with critically ill patients, which causes substantial morbidity and mortality. Currently, there is no effective clinical ARDS treatment strategy. Novel targets that effectively treat ARDS need to be found.Areas covered: Data sources were published articles through June 2019 in PubMed using the following keywords: 'acute respiratory distress syndrome,' 'miRNAs,' 'lncRNAs,' and 'biomarkers.' The selection of studies focused on in cellular model, animal model, and clinical studies of ARDS.Expert commentary: Accumulated evidence revealed that some specific miRNAs and lncRNAs could regulate the signaling pathways of the pathophysiology by targeting specific molecule in ARDS. The differentially expressed miRNAs exert a crucial role in apoptosis of neutrophil, antigen-presenting cells and lung epithelial cell, and the dysfunction of mitochondrial. Recently, the influence of lncRNAs upon miRNA function is also rapidly emerging. In some cases, lncRNA MALAT1 target TLR4 to mediate the p38 MAPK and NF-κB signaling pathway in ARDS rat model. In other cases, lncRNA CASC2 was found to act as a ceRNA of miR-144-3p which directly targeted AQP1 in LPS-induced A549 cell. In addition, other miRNA-lncRNA regulatory patterns in ARDS and novel biomarkers still require deeper research.

20 keywords...

hide…